Mostrar el registro sencillo del ítem

ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study)

dc.rights.licenseopenen_US
dc.contributor.authorFLEURY, H.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCALDATO, Sabrina
dc.contributor.authorRECORDON-PINSON, P.
dc.contributor.authorTHEBAULT, P.
dc.contributor.authorGUIDICELLI, G. L.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorHESSAMFAR, Mojgan
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMORLAT, Philippe
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBONNET, Fabrice
dc.contributor.authorVISENTIN, J.
dc.date.accessioned2021-01-25T11:29:21Z
dc.date.available2021-01-25T11:29:21Z
dc.date.issued2020
dc.identifier.issn1999-4915en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/25982
dc.description.abstractEnWe proposed a new HIV-1 therapeutic vaccine based on conserved cytotoxic T lymphocyte (CTL) epitopes of archived HIV-1 DNA according to their affinity to the dominant HLA-A and -B alleles of the population investigated. Our proposal (Hla Fitted VAC, HFVAC) was composed of 15 peptides originating from the RT, gag and nef parts of proviral DNA. Our aim was to investigate baseline immune reactivity to the vaccine in HIV-1 chronically infected patients at success of antiretroviral therapy (ART) who would be eligible for a therapeutic vaccine. Forty-one patients were tested. Most of them had been infected with HIV-1 subtype B and all had been receiving successful ART for 2 to 20 years. The predominant HLA-A and -B alleles were those of a Caucasian population. ELISPOT was carried out using the HFVAC peptides. In 22 patients, the PD-1 marker was investigated on CD4+ and CD8+ T cells by flow cytometry in order to evaluate global T cell exhaustion. ELISPOT positivity was 65% overall and 69% in patients exhibiting at least one HLA allele fitting with HFVAC. The percentages of CD4+ and CD8+ T cells expressing PD-1 were high (median values 23.70 and 32.60, respectively), but did not seem to be associated with an impairment of the immune response investigated in vitro. In conclusion, reactivity to HFVAC was high in this ART-treated population with dominant HLA alleles, despite potential cellular exhaustion associated with the PD-1 marker.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectIDLIC
dc.subjectMORPH3Eus
dc.title.enART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study)
dc.title.alternativeVirusesen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/v12111256en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33167335en_US
bordeaux.journalVirusesen_US
bordeaux.volume12en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue11en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamIDLICen_US
bordeaux.teamMORPH3Eusen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03120135
hal.version1
hal.date.transferred2021-01-25T11:29:25Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Viruses&rft.date=2020&rft.volume=12&rft.issue=11&rft.eissn=1999-4915&rft.issn=1999-4915&rft.au=FLEURY,%20H.&CALDATO,%20Sabrina&RECORDON-PINSON,%20P.&THEBAULT,%20P.&GUIDICELLI,%20G.%20L.&rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
BPH_Viruses_2020_Fleury.pdf
Tamaño:
572.4Kb
Formato:
PDF
Ver/Abrir
Thumbnail
Nombre:
license_rdf
Tamaño:
914bytes
Formato:
application/rdf+xml
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem